| Literature DB >> 28524077 |
Murali Annamalai1, Stanimira Hristeva2, Martyna Bielska3, Raquel Ortega4, Kamal Kumar5.
Abstract
Despite the great contribution of natural products in the history of successful drug discovery, there are significant limitations that persuade the pharmaceutical industry to evade natural products in drug discovery research. The extreme scarcity as well as structural complexity of natural products renders their practical synthetic access and further modifications extremely challenging. Although other alternative technologies, particularly combinatorial chemistry, were embraced by the pharmaceutical industry to get quick access to a large number of small molecules with simple frameworks that often lack three-dimensional complexity, hardly any success was achieved in the discovery of lead molecules. To acquire chemotypes beholding structural features of natural products, for instance high sp³ character, the synthesis of compound collections based on core-scaffolds of natural products presents a promising strategy. Here, we report a natural product inspired synthesis of six different chemotypes and their derivatives for drug discovery research. These bicyclic hetero- and carbocyclic scaffolds are highly novel, rich in sp³ features and with ideal physicochemical properties to display drug likeness. The functional groups on the scaffolds were exploited further to generate corresponding compound collections. Synthesis of two of these collections exemplified with ca. 350 compounds are each also presented. The whole compound library is being exposed to various biological screenings within the European Lead Factory consortium.Entities:
Keywords: Aza-heterocycles; European Lead Factory; drug discovery; natural products; scaffolds
Mesh:
Substances:
Year: 2017 PMID: 28524077 PMCID: PMC6153746 DOI: 10.3390/molecules22050827
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Biologically active natural products.
Figure 2Natural product inspired bicyclic scaffolds.
Scheme 1Synthesis optimization of an Immunosuppressant FR901483 based scaffold.
Scheme 2Stereoselective synthesis of 1,6-decahydronaphthyridine scaffold.
Scheme 3A lycoposerramine-R alkaloid inspired scaffold synthesis.
Scheme 4A (−)-des-methyl-Carvone derived compound collection.
Scheme 5Synthesis of a carbocyclic scaffold for library synthesis using Hajas–Parrish Ketone.
Scheme 6Production of a compound collection based on bicyclic scaffold 2.
Optimization of the N-debenzylation of 46 and 51.
| Entry | Product | R1 | Reagent | Reaction Time (h) | Yield (%) |
|---|---|---|---|---|---|
| 1 |
| SO2Ph | Pd/C 10% (0.3 Eqv.), H2 (1 atm) | 96 | 0 |
| 2 |
| SO2Ph | 1-Cholorethylchloroformate (2.5 Eqv.) | 96 | 58 |
| 3 |
| SO2-3-Py | 1-Cholorethylchloroformate (2.5 Eqv.) | 48 | 81 |
| 4 |
| SO2Me | Pd/C 10% (0.3 Eqv.), H2 (1 atm) | 48 | 0 |
| 5 |
| SO2Me | 1-Cholorethylchloroformate (2.5 Eqv.) | 48 | 99 |
| 6 |
| SO2-Ph | Pd/C 10% (0.3 Eqv.), H2 (1 atm) | 48 | 96 |
| 7 |
| SO2Me | Pd/C 10% (0.3 Eqv.), H2 (1 atm) | 96 | 28 |
Scheme 7Production and diversification scaffolds 4–5.
Figure 3Production plot for scaffold 2.
Figure 4Production plot for scaffolds 5–6.